Share on StockTwits

Omnicell (NASDAQ:OMCL) VP Marga Ortigas-Wedekind unloaded 2,961 shares of the company’s stock in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $28.17, for a total transaction of $83,411.37. Following the completion of the sale, the vice president now directly owns 43,307 shares in the company, valued at approximately $1,219,958. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Omnicell (NASDAQ:OMCL) traded up 0.67% during mid-day trading on Monday, hitting $28.71. 171,991 shares of the company’s stock traded hands. Omnicell has a 52-week low of $19.29 and a 52-week high of $30.33. The stock has a 50-day moving average of $26.91 and a 200-day moving average of $26.99. The company has a market cap of $1.051 billion and a price-to-earnings ratio of 38.64.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.26 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.24 by $0.02. The company had revenue of $101.80 million for the quarter, compared to the consensus estimate of $97.49 million. During the same quarter in the prior year, the company posted $0.21 earnings per share. The company’s quarterly revenue was up 16.9% on a year-over-year basis. On average, analysts predict that Omnicell will post $1.23 earnings per share for the current fiscal year.

A number of research firms have recently commented on OMCL. Analysts at Topeka Capital Markets initiated coverage on shares of Omnicell in a research note on Thursday, June 12th. They set a “buy” rating and a $30.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Omnicell in a research note on Thursday, May 29th. They now have a $28.00 price target on the stock. Finally, analysts at Stephens initiated coverage on shares of Omnicell in a research note on Tuesday, May 20th. They set an “overweight” rating on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $30.71.

Omnicell, Inc (NASDAQ:OMCL) is a provider of automated solutions for hospital medication and supply management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.